A Randomized Double-blind Clinical Trial on the Efficacy of Transcranial Direct Current Stimulation (tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 339
- 试验地点
- 2
- 主要终点
- Change from baseline to week 24 in Number of Heavy Drinking Days (HDD).
研究概览
简要总结
The study evaluates the efficacy of 1 week of tDCS (5 sessions) placebo in reducing alcohol consumption within the 24 weeks following the treatment in non-abstinent patients with alcohol use disorders versus placebo.
详细描述
340 patients are expected and randomized in two groups: 170 patients with active tDCS and 170 patients with placebo tDCS
Visit 1 : Patients will received one daily session (13:20:13) during 5 consecutive days: current flows continuously twice for 13min with a rest interval (no stimulation) of 20 min.
Visit 1 to 7 : Change from baseline to week 24 in Total Alcohol Consumption (TAC) and Number of Heavy Drinking Days (HDD) will be evaluated in each group.
Evaluation on alcohol consumption (daily drinking diary, alcohol craving and severity) and other assessments like mood, quality of life, safety.
The co-primary outcome of change from baseline in total alcohol consumption AND reduction in number of heavy drinking days at 6 months after treatment and its association with tDCS will be analyzed under the intention-to-treat principle using a mixed model repeated measures (8 times).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have signed and dated the informed consent form
- •Male and female patients over 18 years of age
- •Patients who meet at least two criteria for Alcohol Use Disorder as defined in the Diagnostic and statistical Manual of mental disorder (DSM-5)
- •Patients who are motivated to reduce their alcohol consumption
- •At least one attempt to achieve abstinence (unsuccessful or relapse) or to reduce alcohol consumption
排除标准
- •Breath-alcohol concentration > 0 milligrams per litre of exhaled air at randomization (visit 1)
- •< 6 heavy drinking days in the 4 weeks before randomization (European Medicines Agency, 2010; a day with alcohol consumption ≥ 60 g for men and ≥40 g for women)
- •An average alcohol consumption below medium risk level according to World health Organization (WHO) in the 4 weeks before screening (WHO, 2000; ≤40g/day for men; ≤20g/day for women),
- •More than 3-days abstinence prior to screening and randomization (screening visit and visit 1)
- •A Revised Clinical Institute Withdrawal Assessment for Alcohol score ≥ 10 (indicating the need for medication supported detoxification) at randomization (visit 1)
- •Concomitant treatment with disulfiram, acamprosate, topiramate, baclofen, naltrexone, and nalmefene (<1 month)
- •History of pre-delirium tremens and delirium tremens
- •DSM-5 substance use disorder other than alcohol or nicotine use disorder
- •Acute psychiatric disorders that have required hospitalisation and/or immediate adjustment of psychotropic medications
- •Major depression, as defined by Hamilton Depression (HDRS) scale greater than or equal to 24
- •Recent change in psychotropic medication (< 1 month)
- •Severe chronic psychiatric disorders including schizophrenia, paranoia and bipolar disorder type I and II
- •Advanced liver, kidney, cardiac, or pulmonary disease or other acute serious or unstable medical condition that would compromise patient's participation in the study according to physician's judgment
- •Contra-indications to tDCS: metal in the head, implanted brain medical devices
- •Women who are pregnant or lactating
- •Women of childbearing potential with a positive urine β-human chorionic gonadotrophin pregnancy test at randomization (visit 1)
- •Concurrent participation in other trial
- •Employees of the investigator or trial site
- •Patients protected by law
- •Persons who are not covered by national health insurance
- •Patients, in the opinion of the investigation, not able to complete the TLFB and to complete their daily alcohol consumption in a diary (derived from the TLFB) during the 3 months of the study.
- •Patients who refused to sign "safety" agreement
研究组 & 干预措施
Active tDCS group
Active tDCS
干预措施: Active tDCS (Device)
Placebo tDCS group
Placebo tDCS : Inactive tDCS
干预措施: Placebo tDCS (Device)
结局指标
主要结局
Change from baseline to week 24 in Number of Heavy Drinking Days (HDD).
时间窗: 24 weeks following the treatment
HDD was defined as more than 60 grams of pure alcohol in men and 40 grams in women
Change from baseline to week 24 in Total Alcohol Consumption (TAC)
时间窗: 24 weeks following the treatment
Baseline was defined as alcohol consumption during the 28 days before randomization (visit 1). Baseline will be determined using TLFB (alcohol Timeline Follow-Back), a validated method that retrospectively obtains estimates of daily drinking using a calendar. TAC was defined as mean daily alcohol consumption over 28 days (in g/day)
次要结局
- Change in Quality of Life(Change from baseline at week 4, week 12, and week 24 after the treatment)
- Change in scores for anxiety and depression scales(Change from baseline at week 4, week 12, and week 24 after the treatment)
- Proportion of subjects with a significant categorical shift in World health organization (WHO) risk levels of drinking(Change from baseline during the entire treatment period, and then for each 4-week period after the treatment up to week 24)
- Change in craving/urge to drink assessment(Change from baseline during the entire treatment period, and then for each 4-week period after the treatment up to week 24)
- Proportion of subjects with a 50%, 70% and 90% reduction in alcohol consumption as well as the proportion of patients achieving maintained abstinence (cumulative abstinence duration)(Change from baseline during the entire treatment period, and then for each 4-week period after the treatment up to week 24)
- Change in the level of alcohol dependence severity(Change from baseline during the entire treatment period, and then for each 4-week period after the treatment up to week 24)
- Number of patients with Adverse Events (AEs)(during the entire treatment period, and then for each 4-week period after the treatment up to week 24)
- Change in Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I)(Change from baseline during the entire treatment period, and then for each 4-week period after the treatment up to week 24)
- Change in validated biochemical alcohol consumption markers(Change from baseline at week 4, week 12, and week 24 after the treatment)
- For smokers: change in number of cigarettes smoked/day and craving for tobacco(Change from baseline at week 4, week 12, and week 24 after the treatment)
- Change in cognitive assessment(Change from baseline at week 4, week 12, and week 24 after the treatment)